396 related articles for article (PubMed ID: 21978456)
41. Prognostic impact of PIK3CA protein expression in triple negative breast cancer and its subtypes.
Elfgen C; Reeve K; Moskovszky L; Güth U; Bjelic-Radisic V; Fleisch M; Tausch C; Varga Z
J Cancer Res Clin Oncol; 2019 Aug; 145(8):2051-2059. PubMed ID: 31270600
[TBL] [Abstract][Full Text] [Related]
42. Predictive and prognostic role of tumour-infiltrating lymphocytes in breast cancer patients with different molecular subtypes: a meta-analysis.
Gao ZH; Li CX; Liu M; Jiang JY
BMC Cancer; 2020 Nov; 20(1):1150. PubMed ID: 33238978
[TBL] [Abstract][Full Text] [Related]
43. Novel prognostic markers for patients with triple-negative breast cancer.
Zhou L; Li K; Luo Y; Tian L; Wang M; Li C; Huang Q
Hum Pathol; 2013 Oct; 44(10):2180-7. PubMed ID: 23845466
[TBL] [Abstract][Full Text] [Related]
44. High CD90 (THY-1) expression positively correlates with cell transformation and worse prognosis in basal-like breast cancer tumors.
Lobba ARM; Carreira ACO; Cerqueira OLD; Fujita A; DeOcesano-Pereira C; Osorio CAB; Soares FA; Rameshwar P; Sogayar MC
PLoS One; 2018; 13(6):e0199254. PubMed ID: 29949609
[TBL] [Abstract][Full Text] [Related]
45. A clinicopathological study of triple-negative breast carcinoma in a patient cohort from a tertiary care center in Sri Lanka.
Wijesinghe HD; Fernando J; Senarath U; Wijesinghe GK; S Lokuhetty MD
Indian J Pathol Microbiol; 2020; 63(3):388-396. PubMed ID: 32769327
[TBL] [Abstract][Full Text] [Related]
46. Dual roles for immune metagenes in breast cancer prognosis and therapy prediction.
Alistar A; Chou JW; Nagalla S; Black MA; D'Agostino R; Miller LD
Genome Med; 2014; 6(10):80. PubMed ID: 25419236
[TBL] [Abstract][Full Text] [Related]
47. Biological network-driven gene selection identifies a stromal immune module as a key determinant of triple-negative breast carcinoma prognosis.
Bonsang-Kitzis H; Sadacca B; Hamy-Petit AS; Moarii M; Pinheiro A; Laurent C; Reyal F
Oncoimmunology; 2016; 5(1):e1061176. PubMed ID: 26942074
[TBL] [Abstract][Full Text] [Related]
48. CD8+ lymphocyte infiltration is an independent favorable prognostic indicator in basal-like breast cancer.
Liu S; Lachapelle J; Leung S; Gao D; Foulkes WD; Nielsen TO
Breast Cancer Res; 2012 Mar; 14(2):R48. PubMed ID: 22420471
[TBL] [Abstract][Full Text] [Related]
49. Tumor-infiltrating lymphocytes are significantly associated with better overall survival and disease-free survival in triple-negative but not estrogen receptor-positive breast cancers.
Krishnamurti U; Wetherilt CS; Yang J; Peng L; Li X
Hum Pathol; 2017 Jun; 64():7-12. PubMed ID: 28153508
[TBL] [Abstract][Full Text] [Related]
50. The expression pattern of matrix-producing tumor stroma is of prognostic importance in breast cancer.
Winslow S; Lindquist KE; Edsjö A; Larsson C
BMC Cancer; 2016 Nov; 16(1):841. PubMed ID: 27809802
[TBL] [Abstract][Full Text] [Related]
51. Identification of a prognostic LncRNA signature for ER-positive, ER-negative and triple-negative breast cancers.
Liu D
Breast Cancer Res Treat; 2020 Aug; 183(1):95-105. PubMed ID: 32601968
[TBL] [Abstract][Full Text] [Related]
52. Association of sonographic features and molecular subtypes in predicting breast cancer disease outcomes.
Wang H; Yao J; Zhu Y; Zhan W; Chen X; Shen K
Cancer Med; 2020 Sep; 9(17):6173-6185. PubMed ID: 32657039
[TBL] [Abstract][Full Text] [Related]
53. Comparative microRNA profiling of sporadic and BRCA1 associated basal-like breast cancers.
Yan M; Shield-Artin K; Byrne D; Deb S; Waddell N; ; Haviv I; Fox SB
BMC Cancer; 2015 Jul; 15():506. PubMed ID: 26152113
[TBL] [Abstract][Full Text] [Related]
54. EP300 knockdown reduces cancer stem cell phenotype, tumor growth and metastasis in triple negative breast cancer.
Ring A; Kaur P; Lang JE
BMC Cancer; 2020 Nov; 20(1):1076. PubMed ID: 33167919
[TBL] [Abstract][Full Text] [Related]
55. MiR-34b is associated with clinical outcome in triple-negative breast cancer patients.
Svoboda M; Sana J; Redova M; Navratil J; Palacova M; Fabian P; Slaby O; Vyzula R
Diagn Pathol; 2012 Mar; 7():31. PubMed ID: 22439831
[TBL] [Abstract][Full Text] [Related]
56. Unravelling triple-negative breast cancer molecular heterogeneity using an integrative multiomic analysis.
Bareche Y; Venet D; Ignatiadis M; Aftimos P; Piccart M; Rothe F; Sotiriou C
Ann Oncol; 2018 Apr; 29(4):895-902. PubMed ID: 29365031
[TBL] [Abstract][Full Text] [Related]
57. High ERK protein expression levels correlate with shorter survival in triple-negative breast cancer patients.
Bartholomeusz C; Gonzalez-Angulo AM; Liu P; Hayashi N; Lluch A; Ferrer-Lozano J; Hortobágyi GN
Oncologist; 2012; 17(6):766-74. PubMed ID: 22584435
[TBL] [Abstract][Full Text] [Related]
58. S100A14 is a novel independent prognostic biomarker in the triple-negative breast cancer subtype.
Ehmsen S; Hansen LT; Bak M; Brasch-Andersen C; Ditzel HJ; Leth-Larsen R
Int J Cancer; 2015 Nov; 137(9):2093-103. PubMed ID: 25912829
[TBL] [Abstract][Full Text] [Related]
59. Clinicopathological features of triple-negative breast cancer in Taiwanese women.
Yao-Lung K; Dar-Ren C; Tsai-Wang C
Int J Clin Oncol; 2011 Oct; 16(5):500-5. PubMed ID: 21455625
[TBL] [Abstract][Full Text] [Related]
60. Characteristics of triple-negative breast cancer.
de Ruijter TC; Veeck J; de Hoon JP; van Engeland M; Tjan-Heijnen VC
J Cancer Res Clin Oncol; 2011 Feb; 137(2):183-92. PubMed ID: 21069385
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
